Monday, December 23, 2024
Home
sitemap
AR
FA
googleSearch
Try again
!!!b1!!!
!!!b1!!!
Dean of University
Chancellor of University
Administrative Offices
Education
Education at SKUMS
Undergraduate
Postgraduate
Master's Programs
Ph.D. Programs
Medical
Doctor of Dental Surgery (D.D.S)
General Medicine
Education Development Center
Student's Committee of Medical Education Development
Committee of Research in Education
e-learning
Workshop
Research
Basic Health Sciences Institute
Medical Plants Research Center
Cellular & Molecular Research Center
Clinical Biochemistry Research Center
Research Centers
Cancer Research Center
Research Center in Midwifery & Nursing Sciences
Social Determinants of Health Research Center
Research Center in Health Modeling
Research Development and Evaluation
Scientometrics
Ethics in Research
Library
Technology
Health Technology Incubator Center
Industry and Society Relations
Intellectual Property
Partnership Office
National Partners
International Office
Guidelines
Visa Affairs
Tuition Fees and Expenses
Guiding Rules
University Hospitals
Hajar Hospital
Vali Asr Hospital
Ayatollah Kashani Hospital
University Ranking
Apply now
About
About Iran
About Chaharmahal and Bakhtiari
About SKUMS
SKUMS at a Glance
Former chancellors
2024/12/11
Hemophilia Treatment in Shahrekord with the Latest Medication in the World
Dr. Kiavash Fekri, a pediatric hematology and oncology superspecialist, stated that for the first time in the Chaharmahal and Bakhtiari Province, two hemophilia patients were treated with the latest medication in the world, Hemlibra.
In elaborating on this news, Dr. Fekri explained that Hemlibra (emicizumab), recognized as the most advanced treatment for hemophilia globally, was administered to two patients in the thalassemia ward of the Hajar Educational and Medical Center in Shahrekord.
He emphasized that this medication is currently approved for hemophilia patients with inhibitors to Factor VIII in the country and is the first drug that does not require intravenous administration, as it is injected subcutaneously.
He continued by stating that the prolonged duration of the medication in the patient’s body can last up to one month, which is a significant feature of this drug that has the potential to revolutionize the quality of life for hemophilia patients.
He added that Hemlibra is administered subcutaneously as per the doctor's instructions, typically once a week for the first four weeks, and thereafter is prescribed according to a regular monthly schedule.
Dr. Fekri noted that this medication leads to a reduction in bleeding and allows hemophilia patients to experience a more normal life.
According to him, the introduction of this drug to the province was made possible through extensive efforts by university officials and collaboration with the Ministry of Health, especially considering its high cost, which deserves recognition and appreciation.
number of visits:
339
writer:
Source
Postal Address: Deputy of Research and Technology, Shahrekord University of Medical Sciences, Kashani Blvd., Shahrekord, Iran
Tel: +98-38-33349509
Copyright © 2014 S.K.U.M.S - All rights reserved
×
ورود اعضاء
Powered by
Dorsa
Portal